Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents

Abstract

We describe here new technology that enables noninvasive imaging of therapeutic functional normalization of tumor blood vessels by antiangiogenic agents. Noninvasive variable-magnification in vivofluorescence imaging as well as fluorescence tomography was used to visualize functional vessel normalization. Changes in the same vessel before and after drug treatment were imaged with high resolution in real time. Differences in vascular responses to the mTOR inhibitor rapamycin and to an anti-VEGF antibody were functionally imaged. Tumor vessel normalization was shown by significantly reduced leakiness and subsequent improved tumor delivery of Paclitaxel-BODPY as well as by normalized morphology. The tumor vascular pool agent, AngioSense 750 , was retained only in tumors after either anti-VEGF antibody or rapamycin treatment, as visualized by noninvasive fluorescence tomography. The antiangiogenic therapy normalized vessels, which significantly enhanced the antitumor efficacy of paclitaxel because of increased drug penetration throughout the tumor. The optical imaging technology described here is thus a powerful, noninvasive, time-course imaging tool of functional tumor vessel normalization and its therapeutic consequences. Mol Cancer Ther; 10(7); 1173-84. Ó2011 AACR.

Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer

“…Nevertheless there is strong evidence that transient application of antiangiogenic agents can "normalize" the abnormal tumor microvessels (7,8). This prudent application of antiangiogenic therapy might result in effective uptake of drugs and oxygen in the tumor-enhancing cytotoxic therapeutic outcome in cancer therapy (4,9).…”

Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies

“…Multiple studies have demonstrated evidence of vessel normalization and increased therapeutic uptake. [22][23][24] There are also a series of studies that demonstrate the opposite effect of decreased uptake of therapeutic following anti-VEGF administration. 25 The notion that there is a therapeutic window based on dose and time likely explains these discrepant findings.…”

Optical tomographic imaging of near infrared imaging agents quantifies disease severity and immunomodulation of experimental autoimmune encephalomyelitis in vivo

“…BBB compromise in EAE is well characterized [29], and AngioSense, a validated NIR vascular imaging agent [30,31], offers an opportunity for in vivo imaging of vascular leak into the CNS. In addition, as proteases play a central role in cancer and inflammatory disease processes, we anticipated that protease-activatable NIR imaging agents [32,33] could serve as a sensitive means for detecting neuroinflammation in EAE and changes with therapeutic intervention.…”